1. MARKETS
  2. SECTOR : HEALTHCARE & MEDICAL EQUIPMENT SUPPLIERS
  3. INDUSTRY : MEDICAL SPECIALTIES
  4. STANDARD BIOTOOLS INC
Standard BioTools Inc
XNAS: LAB
1.2M
XNAS Volume

XNAS 05 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Standard BioTools Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Standard BioTools Inc share price target, revenues, EPS, net income and more

Standard BioTools Inc quarterly results: revenue, profit, and P&L – 13 quarter history

  • NEGATIVE

    Quarterly Revenue Standard BioTools Inc Jun-2026 Quarterly Revenue is $20 Million which is growth of -7.6% YoY.

  • POSITIVE

    Quarterly Net Profit Standard BioTools Inc Jun-2026 Quarterly Net Profit is $-27 Million which is growth of 20.0% YoY.

Standard BioTools Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
20.121.223.819.621.840.846.74537.245.528.225.427.7
Cost Of Rev.
9.69.812.410.111.121.124.821.722.321.414.814.214.1
Gross Profit
10.511.311.49.510.619.721.923.314.924.213.411.213.6
⌄
18.420.733.33334.35051.647.656.962.928.328.728.8
Operating Profit
-7.8-9.4-21.9-23.5-23.7-30.3-29.7-24.3-42-38.7-14.9-17.5-15.2
4.63.51.72.12.52.93.33.94.45.2-1.1-1.2-1.1
Profit Before Tax
-21.4-14.6-22-32.9-18.3-26.2-33.8-26.8-45.7-32-19.9-21-16.7
Tax
0.10-35.9-1.2-0.6-0.20.30.10.10.1-0.20.10.3
⌄
-26.8127.119.3-34.7-33.5-26-34.1-26.9-45.7-78.2-19.8-21-17
Diluted NI Avail to Com Stockholders Ann.
-26.8127.119.3-34.7-33.5-26-34.1-26.9-45.7-78.2-19.8-21-17
Basic EPS
-0.10.30.1-0.1-0.1-0.1-0.1-0.1-0.1-0.3-0.3-0.3-0.2
Diluted EPS After ExtraOrdinary
-0-00.1-0.1-0-0.1-0.1-0.1-0.1-0.3-0.2-0.2-0.2
Number Of Shares End
390.9388.2385.1382.6380.5378.2374.7371.5372.3294.179.779.278.7
Net Income Continuing Discontinued Operations
-26.8127.119.3-34.7-33.5-26-34.1-26.9-45.7-32.2-19.8-21-17
Normalized Income
-11-12.816.1-22.6-15.7-23.4-31.6-21.1-39-35.1-13.4-18.1-15.3
Interest Income
-3.51.72.12.52.9-3.94.45.2---
Interest
--00----1.11.21.1
Net Interest Income
4.63.51.72.12.52.93.33.94.45.2-1.1-1.2-1.1
EBIT
-7.8-9.4-22-32.9-18.3-26.2-30-24.3-42-38.7-18.8-19.7-15.6
EBITDA
-6.6-8-20.7-31.4-14.3-22-26-20.4-38.1-33.5-14.9-15.7-12
Reconciled Cost Of Rev.
9.69.812.410.111.121.124.821.722.321.414.814.214.1
Reconciled Depr.
1.31.41.31.544.243.93.95.23.943.6
Profit From Continuing Operations
-26.8127.119.3-34.7-33.5-26-34.1-26.9-45.7-32.2-19.8-21-17
Normalized EBITDA
11-4.9-18-21.9-12.3-19.3-22.9-13-29.6-37.3-8.5-12.1-9.7
*All financials are in USD Million and price data in USD

Standard BioTools Inc competitor comparison and performance snapshot within industry

Standard BioTools Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • NEGATIVE

    Annual Revenue Standard BioTools Inc Dec-2025 Annual Revenue is $85 Million which is growth of -51.1% YoY.

  • POSITIVE

    Annual Net Profit Standard BioTools Inc Dec-2025 Annual Net Profit is $-75 Million which is growth of 46.1% YoY.

Standard BioTools Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
-4.5%
-9.2%
 85.3174.4106.398130.6138.1117.2113101.9104.5114.7
Cost Of Rev. Ann.
-11.1%
-4.8%
41.942.890.255.960.961.254.85351.3504646.6
Gross Profit Ann.
4.6%
-12.6%
42.742.584.350.537.169.483.364.361.75258.468.1
Operating Exp. Ann.
-3.9%
0.2%
105.3135.9219113.5153.3136.8134.4116.1109.8110.3131.6122.2
Operating Profit Ann.
-
-
-62.6-93.3-134.8-63-116.2-67.5-51-51.8-48.2-58.4-73.2-54.1
-
-
11.99.216.9-4.6-4.3-3.8-3.6-4.3-13.9-5.8-5.8-5.8
Other Exp. Ann.
-
-
 -12.6-20.4-6.6-72.47.60.5-10.60.60.4-1.25.2
PBT Ann.
-
-
-91-96.7-138.3-74.2-192.9-63.7-54.1-66.7-61.4-63.8-80.2-54.8
Tax Ann.
-
-
-37-37.90.60.5-2.8-4.4-1.1-1.9-2.4-3.3-4.2-1.5
⌄
-
-
84.9-74.9-184.9-74.7-190.1-59.2-53-64.8-59-60.5-76-53.3
Diluted NI Avail to Com Stockholders Ann.
-
-
84.9-74.9-184.9-74.7-190.1-59.2-53-64.8-59-60.5-76-53.3
EPS Ann.
-
-
 -0.2-0.5-0.9-2.4-0.8-0.7-1-1.5-1.8-2.6-1.9
Diluted EPS Ann.
-
-
 -0.2-0.5-0.9-2.4-0.8-0.7-1-1.5-1.8-2.6-1.9
Number Of Shares End
69.2%
39%
 385.1374.779.779.576.774.369.741.538.829.228.8
Total Exp. Ann.
-5.9%
-1.1%
 178.6309.2169.4214.2198189.2169.1161.1160.3177.6168.9
Net Income Continuing Discontinued Operations Ann.
-
-
84.9-74.9-138.9-74.7-190.1-59.2-53-64.8-59-60.5-76-53.3
Normalized Income Ann.
-
-
-30.3-48.5-126.8-63.9-130.9-59.2-53-53.1-59-60.5-76-59.5
Interest Income Ann.
-
-
 9.220.2---------
Interest Ann.
-
-
 03.34.64.33.83.64.313.95.85.85.8
EBITDA Ann.
-
-
-66.7-85.7-118.1-54.5-173.6-44.3-34.6-46.6-31-39.4-56.4-32.9
Reconciled Cost Of Rev. Ann.
-11.1%
-4.8%
41.942.890.255.960.961.254.85351.3504646.6
Reconciled Depr. Ann.
-9.8%
-7.1%
5.51116.915.21515.615.915.816.618.617.916.1
Profit From Continuing Operations Ann.
-
-
84.9-74.9-138.9-74.7-190.1-59.2-53-64.8-59-60.5-76-53.3
Normalized EBITDA Ann.
-
-
-33.8-68.8-102.9-40.9-113.5-44.3-34.6-34.6-31-39.4-56.4-39.2
*All financials are in USD Million and price data in USD
Total Rev. Ann.
1Y CHG
-51.1%
2Y CAGR
-10.4%
3Y CAGR
-4.5%
5Y CAGR
-9.2%
7Y CAGR
-3.9%
10Y CAGR
-2.9%
Total Revenue Annual is falling faster than historical averages.
Operating Exp. Ann.
1Y CHG
-37.9%
2Y CAGR
9.4%
3Y CAGR
-3.9%
5Y CAGR
0.2%
7Y CAGR
3.1%
10Y CAGR
1.1%
Operating Expenses Annual Cr is falling faster than historical averages.

Standard BioTools Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • NEGATIVE

    Total Shareholders Fund Standard BioTools Inc Dec-2025 Total Shareholders Fund is $424 Million which is growth of -10.1% YoY.

  • NEGATIVE

    Total Assets Standard BioTools Inc Dec-2025 Total Assets is $568 Million which is growth of -7.3% YoY.

Standard BioTools Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
13.3%
11.8%
567.8612.3323.1390.3275.2324.8264.8303.7287.4306.4371.1
⌄
-32.7%
-5%
143.5140.6471.1471.8180.6185.7111.2231.5256.4253.2256.2
⌄
-
25%
424.3471.7-148.1-81.594.6139.1153.672.130.953.2114.9
Total Capitalization Ann.
-
17%
424.6472-144.1-18.7158.8193.3207.4244.2226.2248.2310.6
Tangible Assets Ann.
-
-
424.3331.5-255.8-200.9-41-9.70.4-93.8-147.3-137.4-80.3
Working Capital Ann.
27.9%
40.4%
34631048.9165.422.563.463.389.561.367.2114
Invested Capital Ann.
-
17%
424.6472-84.5-16.6165.6193.3207.4244.2226.2248.2310.6
Tangible Book Value Ann.
-
-
424.3331.5-255.8-200.9-41-9.70.4-93.8-147.3-137.4-80.3
Borrowings Ann.
-33.1%
-20.2%
30.83398.2102.7111.795.460172.1195.2195195.7
Net Debt Ann.
-
-
--11.8-42.6-32.276.7137.2159.9166.6
Share Issued Ann.
71.8%
40.3%
405396.183.479.976.974.57049.338.829.228.8
Number Of Shares End
69.2%
39%
385.1374.779.779.576.774.369.741.538.829.228.8
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
-7.3%
2Y CAGR
32.6%
3Y CAGR
13.3%
5Y CAGR
11.8%
7Y CAGR
9.4%
10Y CAGR
4.3%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
64.3%
2Y CAGR
-0.5%
3Y CAGR
35.6%
5Y CAGR
14.8%
7Y CAGR
16.3%
10Y CAGR
13.7%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-10%
5Y CAGR
25%
7Y CAGR
28.8%
10Y CAGR
14%
Total ShareHolders Funds Annual is falling faster than historical averages.

Standard BioTools Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • POSITIVE

    Book Value Per Share Standard BioTools Inc Book Value Per Share is $1 which is growth of 23.8% YoY.

  • NEUTRAL

    ROE Standard BioTools Inc ROE is 0% which is growth of 0% YoY.

Standard BioTools Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--39.53%-20.93%-57.13%-19.75%-17.99%-22.80%-19.97%-20.39%-22.43%-13.69%
ROE Ann. %
-
-
--114.25%--2,895.85%-50.71%-36.23%-57.41%-114.53%-143.84%-90.39%-40.19%
ROIC %
-
-
--6.3---4.1-7.2-5.6-4.9-4.2-6.4-3.6
OPM Ann. %
-
-
-109.34%-77.25%-59.28%-118.64%-51.66%-36.94%-44.22%-42.64%-57.25%-70.07%-47.20%
Inventory Turnover Ratio Ann.
-
-
-2.92.72.933.33.93.72.82.42.8
Asset Turnover Ann. %
-
-
-0.40.30.30.40.50.40.40.30.30.3
Working Capital Turnover Ann.
-20.6%
-32.9%
0.30.62.20.65.82.21.91.31.71.61
Quick Ratio Ann.
-
-
-51.24.20.91.72.432.32.54
Current Ratio Ann.
-
-
-5.71.54.81.52.22.93.42.83.34.8
Interest Coverage Ratio Ann.
-
-
--40.7-15.3-43.6-15.7-14.2-14.6-3.4-10-12.8-8.4
LT Debt To Equity Ann.
-
-
-0.1--1.10.70.42.46.33.71.7
*All financials are in USD Million and price data in USD

Standard BioTools Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • POSITIVE

    Cash From Operating Activity Standard BioTools Inc Dec-2025 Cash From Operating Activity is $-74 Million which is growth of 48.2% YoY.

  • NEGATIVE

    Net Cash Flow Standard BioTools Inc Dec-2025 Net Cash Flow is $-46 Million which is growth of -139.6% YoY.

Standard BioTools Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
-
-
-74.3-143.5-43.3-89.4-44.1-15.4-35.2-25.2-24.1-39.1-34.7
-
-7.3%
27.4363.220.2-88.1-1240-39.34.717.745.125.7
-86.2%
-50.8%
0.6-102.6-6.8230.81620.92.857.7290.15.3
Cash Plus Cash Eqv. End Of Year Ann.
14.4%
12.1%
123.3168.852.582.329.569.523.795.458.13529.1
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-46.4117.1-29.953.3-40.145.4-71.737.222.66.1-3.7
Cash Plus Cash Eqv. Begin Of Year Ann.
78.9%
48.1%
168.852.582.329.569.523.795.458.13529.133.7
Income Tax Paid Supplemental Data Ann.
-
-
-0.60.80.32.10.50.20.30.20.40.2
Interest Paid Supplemental Data Ann.
-
-
03.13.83.53.23.13.55.55.55.55.5
Capex Ann.
-
-
-8.3-8.4-2.8-3.8-13.3-12.7-2.5-0.4-1.6-5.1-10.7
Issuance Of Capital Stock Ann.
-
-
-22520.2-59.5290.1-
Issuance Of Debt Ann.
-
-
-2516.855---
Repayment Of Debt Ann.
-
-
-63.2-2.1-6.8-0.5-51.8----
Repurchase Of Capital Stock Ann.
-
-
-40.5-5.4-0.6-------
Free Cash Flow Ann.
-
-
-82.7-151.8-46.1-93.2-57.3-28.1-37.7-25.6-25.7-44.2-45.4
*All financials are in USD Million and price data in USD
Cash from Investing Act. Ann.
1Y CHG
-92.5%
2Y CAGR
16.5%
5Y CAGR
-7.3%
7Y CAGR
28.6%
10Y CAGR
0.6%
Cash from Investing Activity Annual is falling faster than historical averages.
Cash from Financing Act. Ann.
3Y CAGR
-86.2%
5Y CAGR
-50.8%
7Y CAGR
-47.9%
10Y CAGR
-19.6%
Cash from Financing Annual Activity growth is higher than historical averages.